FGF Receptors: Cancer Biology and Therapeutics

@article{Katoh2014FGFRC,
  title={FGF Receptors: Cancer Biology and Therapeutics},
  author={Masaru Katoh and Hitoshi Nakagama},
  journal={Medicinal Research Reviews},
  year={2014},
  volume={34}
}
  • M. Katoh, H. Nakagama
  • Published 1 March 2014
  • Biology, Medicine, Chemistry
  • Medicinal Research Reviews
Fibroblast growth factors (FGFs) are involved in a variety of cellular processes, such as stemness, proliferation, anti‐apoptosis, drug resistance, and angiogenesis. Here, FGF signaling network, cancer genetics/genomics of FGF receptors (FGFRs), and FGFR‐targeted therapeutics will be reviewed. FGF signaling to RAS‐MAPK branch and canonical WNT signaling cascade mutually regulate transcription programming. FGF signaling to PI3K‐AKT branch and Hedgehog, Notch, TGFβ, and noncanonical WNT signaling… 
Therapeutics Targeting FGF Signaling Network in Human Diseases.
  • M. Katoh
  • Biology, Medicine
    Trends in pharmacological sciences
  • 2016
Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression.
TLDR
This review focuses on recent advances in the relationship between FGFR disorders and tumorigenesis, and examines the role of methylation, histone remodeling, microRNA regulation, single nucleotide polymorphisms, amplification, and fusion of FGFRs with other genes.
Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?
TLDR
The incorporation of specific patient selection biomakers with the rationale for therapeutic intervention with FGFR-targeted therapy in breast cancer is endorsed.
An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness
TLDR
It is demonstrated that an FGFR/AKT/SOX2 axis controls cancer stemness in PDAC and therefore may represent an important therapeutic target in the fight against this very aggressive form of cancer.
Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
TLDR
Deregulation of FGF/FGFR-related mechanisms in human disease and tumor progression leading to the presentation of emerging therapeutic approaches, resistance to FGFR targeting, and clinical potentials of individual FGF family in several human cancers are described.
Fibroblast Growth Factors and their Emerging Cancer-Related Aspects
TLDR
Overexpression of FGFs and FGFRs has been correlated with advanced tumor forms, mainly prostate, mammary gland, bladder and renal cell carcinomas.
Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
TLDR
The current understanding of the FGF/FGFRs system and the oncogenic effect of FGFR fusions is reviewed, promising inhibitors under clinical development for patients with FG FR fusions are summarized, and the challenges in this field are highlighted.
Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
TLDR
Research progress regarding the molecular implications of FGF/FGFR-mediated signaling and the development of FGFR-targeted therapeutics in hepatocarcinogenesis are summarized.
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
TLDR
An overview of the role of FGFR signaling in tumorigenesis, tumor progression, proliferation, and chemoresistance is provided and the accumulating evidence that demonstrates the effectiveness of using clinical therapeutic agents to inhibitFGFR signaling for the treatment of gastric cancer is discussed.
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
  • M. Katoh
  • Biology, Medicine
    International journal of molecular medicine
  • 2016
TLDR
The dual inhibition of FGF and CSF1 or VEGF signaling is expected to enhance the antitumor effects through the targeting of immune evasion and angiogenesis in the tumor microenvironment.
...
...

References

SHOWING 1-10 OF 183 REFERENCES
Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics
  • M. Katoh
  • Biology, Medicine
    Expert review of anticancer therapy
  • 2010
TLDR
Clinical application of small-molecule FGFR inhibitors could improve the prognosis of FGFR-driven cancer patients and prescribe broad-range tyrosine kinase inhibitors targeting FGFRs and other receptors.
Cancer genomics and genetics of FGFR2 (Review).
  • M. Katoh
  • Biology, Medicine
    International journal of oncology
  • 2008
TLDR
Genomics and genetics ofFGFR2, and therapeutics targeted to FGFR2 will be reviewed, and AZD2171 is the most promising anti-cancer drug.
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
  • Y. Katoh, M. Katoh
  • Biology, Medicine
    International journal of molecular medicine
  • 2009
TLDR
FGFR2 signaling dysregulation due to the accumulation of epigenetic modifications and genetic alterations during chronic inflammation, smoking, increased caloric uptake, and decreased exercise leads to carcinogenesis and PD173074, SU5402, AZD2171, and Ki23057 are small-molecule FGFR inhibitors.
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.
  • M. Katoh
  • Medicine, Biology
    The Journal of investigative dermatology
  • 2009
TLDR
Dysregulation of FGFR2 results in a spectrum of bone and skin pathologies and several types of cancer, including melanoma and endometrial uterine cancer.
Targeting mutant fibroblast growth factor receptors in cancer.
The role of fibroblast growth factors in tumor growth.
TLDR
FGF has the potential to overcome chemotherapy resistance highlighting that chemotherapy may be more effective when used in combination with FGF inhibitor therapy and FGFRs have variable activity in promoting angiogenesis.
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
TLDR
FGF19/FGFR4 cross-talk with beta-catenin and that pathway intervention reduces tumor growth is highlighted and wild-type beta-Catenin is accessible for modulation.
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.
TLDR
The results suggest that cooperation of the FGF and Wnt pathways in mammary tumorigenesis is based on the activation of protein translational pathways that result in increased expression of Wnt/beta-catenin target genes (at the level of protein translation).
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10
TLDR
The results suggest that the increased breast cancer risk associated with SNP rs2981578 is due to increased FGFR2 signaling activity in stromal fibroblasts, possibly also involving paracrine FGF10 signaling.
...
...